Distributor Opportunities
BioPorto is looking for distributor partnerships in select markets for The NGAL Test, research use only antibodies and ELISA kits.

BioPorto is an in vitro diagnostics firm focused on actionable biomarkers.
bioporto.comCrawled Nov 19, 2026
BioPorto is looking for distributor partnerships in select markets for The NGAL Test, research use only antibodies and ELISA kits.
Acute kidney injury (AKI) is a rapid loss of kidney function, which can occur as a complication of another serious illness or intervention.
The page describes AKI clinical manifestations and risk factors relevant to multiple medical specialties.
Clinical research support advancing scientific knowledge, exploring new therapeutic approaches, and generating real-world evidence that can contribute to improved patient care.
BioPorto offers NGAL products for clinical chemistry, including FDA-cleared ProNephro AKI and CE-marked NGAL tests for use in the EU, Canada, and Korea.
The page summarizes recent strategic updates, collaborations, FDA clearances, and leadership changes at BioPorto.
For the latest BioPorto news including press releases and videos.
The KDIGO 2026 draft guideline expands AKI definitions to include Acute Kidney Disease and integrates biomarkers. Public review closes April 27, 2026.
BioPorto offers career opportunities for a team focused on diagnostic and research tools for health improvement.
BioPorto's Nomination & Remuneration Committee is established in accordance with Danish Corporate Governance Recommendations 3.4.4. and 4.
BioPorto's Audit Committee is established in accordance with the Danish Corporate Governance Recommendations 3.4.3.
The page lists the members of the BioPorto board of directors.
BioPorto’s executive team develops the business according to the company’s strategic plan.
BioPorto's Product Development & Strategy Committee provides oversight of product development, clinical evaluation, regulatory strategy, and commercialization.
BioPorto holds ISO 13485:2016 and MDSAP quality certifications.
BioPorto's governance including Articles of Association, Risk Management, Social Responsibility, and Remuneration.
The page introduces the leadership team and board of directors shaping research tools into clinically actionable assays.
BioPorto provides customer support for orders, technical issues, and general inquiries.
BioPorto AS handles investor relations inquiries.
BioPorto invites meetings to discuss customer needs.
BioPorto develops NGAL clinical chemistry assays, ELISA kits, and antibodies to improve kidney health.
BioPorto’s Code of Conduct emphasizes legal compliance, anti-corruption, fair competition, and human rights.
BioPorto Diagnostics operates under a Comprehensive Compliance Program tailored to its in vitro medical device business.
Bioporto structures its business in accordance with commercial and economic activities and supporting sustainable development goals.
BioPorto outlines its data governance policies and legal compliance requirements.
BioPorto's Whistleblower Policy has been adopted by the Board of Directors and became effective on 29 March 2023.
BioPorto reports sustained growth in its NGAL (Neutrophil Gelatinase-Associated Lipocalin) biomarker program. The company advances its U.S. Adult Validation Study, a clinical milestone for expanding NGAL’s diagnostic applications. NGAL is under investigation for acute kidney injury and other inflammatory conditions.
BioPorto has begun enrolling patients in the ProNephro AKI® U.S. Adult Urine NGAL Validation Study, a clinical trial assessing urine NGAL as a biomarker for acute kidney injury (AKI). The study aims to validate diagnostic performance in adult patients. This marks a key step in advancing BioPorto’s kidney disease diagnostics portfolio.
BioPorto A/S reports its financial and operational performance for the second quarter and first half of 2026. The company provides updates on revenue, research progress, and strategic initiatives in its biotech portfolio. Key metrics and outlook are included in the interim results.
BioPorto has enrolled its first U.S. clinical site for the ProNephro AKI® study, validating urine NGAL biomarkers in adult patients with acute kidney injury (AKI). The trial assesses the diagnostic accuracy of NGAL in urine samples to support early AKI detection. BioPorto develops renal diagnostics for clinical decision-making.
BioPorto and Roche Diagnostics have made ProNephro AKI™ (NGAL) commercially available to US laboratories. The test detects Acute Kidney Injury (AKI) early, leveraging NGAL biomarkers. This collaboration expands access to the diagnostic tool in the US market.
BioPorto A/S appoints a new CEO to formalize its succession planning strategy. The move follows a structured approach to ensure leadership continuity within the company. BioPorto specializes in biopharmaceutical research and development, focusing on innovative drug discovery solutions.